Find out more about the availability of cancer medicines in
- Enter in the search engine or select from the list
Select the type of cancer and see a full compilation of pharmaceutical therapies authorized by European Medicines Agency (EMA) in last 15 years and recommended by the European Society for Medical Oncology (or enter the medicine and check if it is reimbursed).
- Download or print out the list
Medicines increasing the chances of your successful recovery might be on the list.
- Consult the list with your doctor
Ask your doctor to verify the possible medicines and indicate the once which can be the most effective in your case. The list may also include non-reimbursed therapies. In such a situation contact us - we will help you find a solution.
non-Hodgkin lymphoma
How to read the list?Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.
-
Lisocabtagene maraleucelLisocabtagene maraleucel is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. Lisocabtagene maraleucel is indicated for the treatment of adult patients with relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy.No reimbursementThe drug in this indication is not refundedESMOSubstance is recommended by ESMO.
-
PirtobrutinibPirtobrutinib as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.No reimbursementThe drug in this indication is not refundedESMOSubstance is recommended by ESMO.
-
ZanubrutinibZanubrutinib in combination with obinutuzumab is indicated for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.No reimbursementThe drug in this indication is not refundedESMOSubstance is recommended by ESMO.
-
Axicabtagene ciloleucelAxicabtagene ciloleucel is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Axicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.Reimbursement with restrictionsThe drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
TisagenlecleucelTisagenlecleucel is indicated for the treatment of: - Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. - Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.Reimbursement with restrictionsThe drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
EpcoritamabEpcoritamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Epcoritamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.Reimbursement with restrictionsThe drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
IbrutinibIbrutinib as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
ObinutuzumabObinutuzumab in combination with chemotherapy, followed by Obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced FL. Obinutuzumab in combination with bendamustine followed by Obinutuzumab maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
LenalidomideLenalidomide in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Lenalidomide as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
Polatuzumab vedotinPolatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polatuzumab vedotin in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
Brexucabtagene autoleucelMantle cell lymphoma Brexucabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
TafasitamabTafasitamab is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
MosunetuzumabMosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
Loncastuximab tesirineLoncastuximab tesirine as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
GlofitamabGlofitamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.